This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Study to Assess the Safety and Efficacy of ZPL38...
Clinical trial

A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

Read time: 2 mins
Last updated:14th Nov 2018
Identifier: NCT03517566

The purpose of this study is to assess ZPL389 efficacy and safety in subjects with moderate to severe atopic dermatitis.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 360 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Multicenter Dose Ranging Study to Assess the Safety and Efficacy of Multiple Oral ZPL389 Doses in Patients With Moderate to Severe Atopic Dermatitis (ZEST Trial)
Actual Study Start Date: November 14, 2018
Estimated Primary Completion Date: December 18, 2020
Estimated Study Completion Date: January 15, 2021

Arms:
- Placebo Comparator:
placebo
- Experimental: ZPL389 Dose 1
- Experimental: ZPL389 Dose 2
- Experimental: ZPL389 Dose 3
- Experimental: ZPL389 Dose 4

Category Value
Date last updated at source 2019-10-01
Study type(s) Interventional
Expected enrolment 360
Study start date 2018-11-14
Estimated primary completion date 2020-12-18

View full details